Jeannie S Lee

US Patent:

20100203632, Aug 12, 2010

Filed:

Jan 24, 2008

Appl. No.:

12/523018

Inventors:

Jeannie T. Lee - Weston MA, US

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

C12N 5/07
C12N 5/00
C12N 5/071
C07H 21/02

US Classification:

435354, 435325, 435366, 536 231

Abstract:

Disclosed herein are methods for controlling stem cell differentiation through the introduction of transgenes having Xic, Tsix, Xite, or Xic flanking region sequences to block differentiation and the removal of the transgenes to allow differentiation. Also disclosed are small RNA molecules and methods for using the small RNA molecules to control stem cell differentiation. Also disclosed are stem cells genetically modified by the introduction of Xic, Tsix, XUe, or Xic flanking region sequences.

US Patent:

20090215872, Aug 27, 2009

Filed:

Jun 30, 2006

Appl. No.:

11/988321

Inventors:

Jeannie T. Lee - Weston MA, US

International Classification:

C12N 15/09
C12N 5/10
C07H 21/02
A61K 31/7088
C12N 15/63
A61P 43/00

US Classification:

514 44 R, 435377, 435366, 536 231, 4353201

Abstract:

Disclosed herein are methods for controlling stem cell differentiation through the introduction of transgenes having Xic, Tsix, or Xite sequences to block differentiation and the removal of the transgenes to allow differentiation. Also disclosed are small RNA molecules and methods for using the small RNA molecules to control stem cell differentiation. Also disclosed are stem cells genetically modified by the introduction of Xic, Tsix, or Xite sequences.

US Patent:

20210102203, Apr 8, 2021

Filed:

May 18, 2020

Appl. No.:

16/876271

Inventors:

- Lexington MA, US
- Boston MA, US
James McSwiggen - Arlington MA, US
Jeannie T. Lee - Boston MA, US

Assignee:

Translate Bio MA, Inc. - Lexington MA
The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

International Classification:

C12N 15/113
A61K 47/61
A61K 47/64
A61K 31/7115
A61K 31/712
A61K 31/7125
C07H 21/00
C07H 21/02
C07H 21/04
A61K 47/54

Abstract:

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.

US Patent:

20200040333, Feb 6, 2020

Filed:

Jan 16, 2018

Appl. No.:

15/872684

Inventors:

- Cambridge MA, US
- Boston MA, US
James McSwiggen - Arlington MA, US
Jeannie T. Lee - Boston MA, US

Assignee:

Translate Bio MA, Inc. - Cambridge MA
The General Hospital Corporation - Boston MA

International Classification:

C12N 15/113
A61K 47/64
C07H 21/00
A61K 31/7125
A61K 31/712
A61K 31/7115
C07H 21/04
C07H 21/02
A61K 47/61

Abstract:

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.

US Patent:

20180223282, Aug 9, 2018

Filed:

Oct 19, 2017

Appl. No.:

15/787876

Inventors:

- Cambridge MA, US
- Boston MA, US
James McSwiggen - Arlington MA, US
Jeannie T. Lee - Boston MA, US

Assignee:

RaNA Therapeutics, Inc. - Cambridge MA
The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

International Classification:

C12N 15/113
C07H 21/00
A61K 31/7125
A61K 31/712
A61K 31/7115
C07H 21/04
C07H 21/02

Abstract:

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.

US Patent:

20150344910, Dec 3, 2015

Filed:

Aug 3, 2015

Appl. No.:

14/816605

Inventors:

- Boston MA, US
Jeannie T. LEE - Weston MA, US

International Classification:

C12N 15/85
C12N 15/113

Abstract:

Disclosed herein are methods for controlling stem cell differentiation through the introduction of transgenes having Xic, Tsix, or Xite sequences to block differentiation and the removal of the transgenes to allow differentiation. Also disclosed are small RNA molecules and methods for using the small RNA molecules to control stem cell differentiation. Also disclosed are stem cells genetically modified by the introduction of Xic, Tsix, or Xite sequences.

US Patent:

20150252364, Sep 10, 2015

Filed:

May 16, 2013

Appl. No.:

14/401194

Inventors:

- Cambridge MA, US
- Boston MA, US
James McSwiggen - Arlington MA, US
Jeannie T. Lee - Boston MA, US

Assignee:

RaNA Therapeutics, Inc. - Cambridge MA
The General Hospital Corporation d/b/a Massachusetts General Hospital - Boston MA

International Classification:

C12N 15/113

Abstract:

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.

US Patent:

20150232836, Aug 20, 2015

Filed:

May 16, 2013

Appl. No.:

14/401240

Inventors:

- Cambridge MA, US
- Boston MA, US
James McSwiggen - Arlington MA, US
Jeannie T. Lee - Boston MA, US

Assignee:

RaNA Therapeutics, inc. - Cambridge MA
The General Hospital Corporation - Boston MA

International Classification:

C12N 15/113

Abstract:

Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene.